| Year | 2023 | 2022 |
|---|---|---|
| CF from Operating Activities | 2.3B | 2.37B |
| Net Income | 3.14B | 3.38B |
| Depreciation & Amortization | 742.7M | 518.53M |
| Deferred Income Taxes | 0 | 0 |
| Stock Based Compensation | 0 | 0 |
| Change in Working Capital | -1.26B | -1.11B |
| Accounts Receivable | -371.67M | -275.18M |
| Inventory | -1.13B | -448.5M |
| Accounts Payable | 526.89M | 224.23M |
| Other Working Capital | -290.41M | -615.2M |
| Other Non-Cash Items | -313.71M | -406.29M |
| CF from Investing Activities | 2.3B | 2.37B |
| Investments in Property, Plant & Equipment | -2.09B | -536.31M |
| Net Acquisitions | 0 | -266.1M |
| Investment Purchases | -370.01M | -1.9B |
| Sales/Maturities of Investments | 732.78M | 2.16B |
| Other Investing Activites | 317.21M | -2.06B |
| CF from Financing Activities | -687.27M | 1.98B |
| Debt Repayment | -124.97M | 52.96M |
| Common Stock Issued | 0 | 2.75B |
| Common Stock Repurchased | 0 | -451.66M |
| Dividends Paid | -226.58M | -101.71M |
| Other Financing Activites | -335.72M | -318.39M |
| Free Cash Flow | 215.69M | 1.84B |
| Operating Cash Flow | 2.3B | 2.37B |
| Capital Expenditures | -2.09B | -536.31M |
| Cash at Beginning of Period | 3.82B | 2.06B |
| Cash at End of Period | 4.03B | 3.82B |
| Net Change In Cash | 208.4M | 1.76B |
Marksans Pharma Limited
MARKSANS.NS
NSE
205.58INR11.43 (6.52%)
MARKSANS.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 10.91B | 5.09B |
| Net Income | 3.14B | 2.66B |
| Stock Repurchases | 0 | -451.66M |
| Dividend Paid | -226.58M | -101.71M |
| Retained Earnings | 10.69B | 10.91B |
| Other Distributions | -450.69M | 5.27B |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 6.93B | 3.87B |
| Annual Depreciation | 742.7M | 518.53M |
| Capital Expenditure | -2.09B | -536.31M |
| Net PPE | 8.28B | 3.89B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 10.1M | 84.64M |
| Goodwill (Previous Year) | 384.89M | 300.25M |
| Goodwill | 394.99M | 384.89M |